PHATHOM PHARMACEUTICALS, INC. financials

PHAT CIK 0001783183

Source: EDGAR filings · Built 2026-06-02T03:49:15Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -167.00M -266.90M -139.21M -147.57M -148.78M -70.73M
EBITDA -159.35M -276.67M -166.74M -171.82M -134.56M -125.34M
Working Capital 96.93M 274.41M 358.65M 134.28M 167.60M 235.84M
Net Debt 81.83M -95.35M -242.36M -58.31M -91.92M -238.48M
Gross Margin 87.09% 85.57% 75.51%
Operating Margin -91.36% -502.18% -24532.55%
Net Margin -126.35% -605.09% -29558.94%
Return on Equity (ROE) 50.49% 131.84% 277.07% 264.29% -199.41% -66.44%
Return on Assets (ROA) -85.37% -88.37% -48.71% -119.97% -75.96% -43.74%
Current Ratio 1.73× 4.20× 10.25× 6.12× 9.86× 5.25×
Debt-to-Equity -0.48× -0.80× -1.91× -1.30× 1.27× 0.25×
Effective Tax Rate 0.00% 0.00%
Cash Conversion Ratio 0.75× 0.80× 0.68× 0.74× 1.03× 0.54×
Accruals Ratio -0.21× -0.18× -0.15× -0.31× 0.02× -0.20×
SBC % of Revenue 16.40% 43.52% 6601.91%
CapEx Coverage -728.28× -1976.07× -84.20× -140.76× -452.61× -67.01×
Free Cash Flow Per Share $-2.29 $-4.22 $-2.71 $-3.77 $-4.02 $-2.13

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 6.77× 10.07× 776.05×
P/B 8.32× 4.88×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 175.11M 55.25M 682.00K 0
Cost of Revenue 22.60M 7.97M 167.00K 0
Gross Profit 152.51M 47.28M 515.00K 0
Research and Development Expense 32.78M 34.08M 49.90M 71.44M 72.34M 98.15M
Selling, General and Administrative Expense 279.72M 290.66M 117.93M 101.00M
Operating Expenses 312.50M 324.75M 167.83M 172.44M 135.08M 125.67M
Operating Income (Loss) -159.99M -277.47M -167.31M -172.44M -135.08M -125.67M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -221.25M -334.33M -201.59M -197.72M -143.88M -129.07M
Earnings Per Share, Basic $-3.03 $-5.29 $-3.93 $-5.05 $-3.89
Weighted Average Number of Shares Outstanding, Basic 72.92M 63.18M 51.29M 39.12M 37.00M
Earnings Per Share, Diluted $-3.03 $-5.29 $-3.93 $-5.05 $-3.89
Weighted Average Number of Shares Outstanding, Diluted 72.92M 63.18M 51.29M 39.12M 37.00M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 129.97M 297.26M 381.39M 155.38M 183.26M 287.50M
Assets, Current 228.97M 360.13M 397.43M 160.51M 186.53M 291.37M
Assets 259.15M 378.32M 413.84M 164.81M 189.43M 295.11M
Long-term Debt 209.09M 201.41M 137.84M 95.26M 89.67M 46.99M
Liabilities, Current 132.04M 85.73M 38.78M 26.24M 18.92M 55.52M
Long-term Debt, Excluding Current Maturities 209.09M 201.41M 137.84M 95.26M 89.67M 39.63M
Liabilities 697.32M 631.90M 486.60M 239.62M 117.28M 100.84M
Stockholders' Equity Attributable to Parent -438.17M -253.58M -72.76M -74.81M 72.16M 194.27M
Common Stock, Shares, Outstanding 71.42M 68.52M 57.97M 41.47M 30.51M 28.52M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -166.78M -266.77M -137.58M -146.53M -148.46M -69.69M
Payments to Acquire Property, Plant, and Equipment 229.00K 135.00K 1.63M 1.04M 328.00K 1.04M
Net Cash Provided by (Used in) Investing Activities -229.00K -135.00K -1.63M -1.04M -328.00K -1.04M
Net Cash Provided by (Used in) Financing Activities -288.00K 182.77M 367.58M 120.04M 44.71M 114.46M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PHAT CIK 0001783183), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DCO

DUCOMMUN INCORPORATED

MSEX

MIDDLESEX WATER COMPANY

USGO

U.S. GOLDMINING INC.